Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Significant Decrease in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 231,318 shares, a decrease of 93.2% from the July 15th total of 3,421,439 shares. Currently, 20.0% of the shares of the stock are sold short. Based on an average trading volume of 665,888 shares, the short-interest ratio is presently 0.3 days.

Calidi Biotherapeutics Price Performance

Shares of Calidi Biotherapeutics stock traded down $0.04 on Wednesday, hitting $1.60. The company had a trading volume of 84,490 shares, compared to its average volume of 229,679. Calidi Biotherapeutics has a 52 week low of $1.48 and a 52 week high of $96.95. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.92 and a quick ratio of 1.92. The company has a market cap of $1.94 million, a PE ratio of -0.02 and a beta of 1.33. The business has a 50-day simple moving average of $2.19 and a 200-day simple moving average of $5.46.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its earnings results on Thursday, May 14th. The company reported ($6.88) EPS for the quarter.

Institutional Trading of Calidi Biotherapeutics

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in Calidi Biotherapeutics during the fourth quarter worth about $25,000. Geode Capital Management LLC lifted its holdings in Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares during the last quarter. Finally, DRW Securities LLC bought a new position in shares of Calidi Biotherapeutics during the 4th quarter valued at about $173,000. Institutional investors and hedge funds own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.